Recipharm has signed an agreement with Daewoong, a Korean-based pharmaceutical company with a strong presence in respiratory therapeutics, for a ten year extension of its existing contract, through to 2025, for the manufacture and supply of Erdosteine API. The finished Erdosteine product is manufactured by Daewoong Pharmaceutical at its Korean facilities.  Daewoong will annually purchase minimum API quantities of Erdosteine worth a total of about €25 million from Edmond Pharma, a Recipharm Gr...